CN107002113A - 脂肪肝病的生物标志物和其使用方法 - Google Patents

脂肪肝病的生物标志物和其使用方法 Download PDF

Info

Publication number
CN107002113A
CN107002113A CN201580063349.2A CN201580063349A CN107002113A CN 107002113 A CN107002113 A CN 107002113A CN 201580063349 A CN201580063349 A CN 201580063349A CN 107002113 A CN107002113 A CN 107002113A
Authority
CN
China
Prior art keywords
biomarkers
subject
sample
level
liver diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580063349.2A
Other languages
English (en)
Chinese (zh)
Inventor
R·佩里肖恩
L·N·贝尔
J·伍尔夫
U·T·恩格扬
S·M·瓦特金斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Publication of CN107002113A publication Critical patent/CN107002113A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580063349.2A 2014-11-19 2015-11-18 脂肪肝病的生物标志物和其使用方法 Pending CN107002113A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462081903P 2014-11-19 2014-11-19
US62/081,903 2014-11-19
US201562141494P 2015-04-01 2015-04-01
US62/141,494 2015-04-01
PCT/US2015/061215 WO2016081534A1 (en) 2014-11-19 2015-11-18 Biomarkers for fatty liver disease and methods using the same

Publications (1)

Publication Number Publication Date
CN107002113A true CN107002113A (zh) 2017-08-01

Family

ID=56014479

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580063349.2A Pending CN107002113A (zh) 2014-11-19 2015-11-18 脂肪肝病的生物标志物和其使用方法

Country Status (5)

Country Link
US (1) US20170370954A1 (enExample)
EP (1) EP3221463A4 (enExample)
JP (1) JP2018502286A (enExample)
CN (1) CN107002113A (enExample)
WO (1) WO2016081534A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI721462B (zh) * 2018-09-26 2021-03-11 日商島津製作所股份有限公司 非酒精性脂肪肝疾病的檢測方法、非酒精性脂肪肝疾病檢測用試劑盒和非酒精性脂肪肝疾病檢測用生物標記
CN112712896A (zh) * 2021-03-26 2021-04-27 深圳市绘云生物科技有限公司 用于检测非酒精性脂肪性肝病状态的诊断装置
CN113160983A (zh) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 一种代谢相关脂肪性肝病临床预测模型
CN113195732A (zh) * 2018-12-19 2021-07-30 阿斯利康(瑞典)有限公司 Pnpla3表达的生物标记
WO2023097510A1 (zh) * 2021-11-30 2023-06-08 江苏品生医疗科技集团有限公司 预测受试者患有糖尿病的可能性的标记物及其应用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170193810A1 (en) * 2016-01-05 2017-07-06 Wizr Llc Video event detection and notification
CN115236166A (zh) 2016-05-29 2022-10-25 深圳市绘云生物科技有限公司 肝病相关生物标志物和其使用方法
WO2017210097A1 (en) 2016-06-02 2017-12-07 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
WO2018007422A1 (en) * 2016-07-05 2018-01-11 One Way Liver,S.L. Identification of human non-alcoholic fatty liver disease (nafld) subtypes
EP3267199A1 (en) * 2016-07-06 2018-01-10 One Way Liver S.L. Diagnostic methods based on lipid profiles
US12313634B2 (en) 2017-11-20 2025-05-27 Zora Biosciences Oy Methods for prediction and early detection of diabetes
EP3502703A1 (en) 2017-12-22 2019-06-26 Metanomics Health GmbH Method for the assessment of nafld
CN112136043B (zh) * 2018-04-04 2024-03-22 梅塔博隆股份有限公司 用于检测和定量肝功能代谢产物的质谱测定方法
US20210267939A1 (en) * 2018-06-18 2021-09-02 Duke University Compositions and methods for treating nafld/nash and related disease phenotypes
JP7029139B2 (ja) * 2018-08-23 2022-03-03 デンカ株式会社 非アルコール性脂肪性肝炎の検出を補助する方法
WO2020044500A1 (ja) * 2018-08-30 2020-03-05 国立大学法人 東京大学 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
WO2020044497A1 (ja) * 2018-08-30 2020-03-05 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
KR102105880B1 (ko) * 2018-10-26 2020-04-29 서울대학교병원 비알코올 지방간 질환의 조직학적 중증도 진단 또는 예후 측정에 관한 정보 제공 방법
JP6592627B1 (ja) * 2019-03-12 2019-10-16 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
JP6592628B1 (ja) * 2019-03-12 2019-10-16 国立大学法人 東京大学 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
KR102280261B1 (ko) * 2019-07-16 2021-07-20 이화여자대학교 산학협력단 대사체 분석을 이용한 간질환의 진단 방법
CN110507670B (zh) * 2019-09-24 2023-04-07 江西天元药业有限公司 精制熊胆粉及预防治疗肝病肝纤维化改善肝功能的用途
US20230064246A1 (en) * 2019-11-05 2023-03-02 Beth Israel Deaconess Medical Center, Inc. Diagnosis and treatment of nafld and liver fibrosis
JP7627467B2 (ja) * 2020-02-04 2025-02-06 デンカ株式会社 非アルコール性脂肪肝炎の検出を補助する方法
CN111562321B (zh) * 2020-04-16 2022-10-28 广东省结核病控制中心 用于检测活动性肺结核的粪便代谢物及其检测系统
WO2022198071A1 (en) * 2021-03-18 2022-09-22 Complete Omics Inc. Methods and systems for detecting and quantifying large number of molecule biomarkers from a body fluid sample
EP4553503A1 (en) * 2022-06-07 2025-05-14 Nitto Denko Corporation Marker for diagnosing non-alcoholic fatty liver disease (nafld) or non-alcoholic steatohepatitis (nash)
WO2024237259A1 (ja) * 2023-05-17 2024-11-21 株式会社島津製作所 非アルコール性脂肪肝疾患の発症リスク評価方法、および、バイオマーカー
WO2024237258A1 (ja) * 2023-05-17 2024-11-21 株式会社島津製作所 非アルコール性脂肪肝疾患の識別方法、および、バイオマーカー
WO2025008466A1 (en) 2023-07-06 2025-01-09 Numares Ag Use of a biomarker for determining the risk of an individual to have hepatic encephalopathy
WO2025008467A2 (en) 2023-07-06 2025-01-09 Numares Ag Use of a marker or a marker set for determining the risk of an individual to have a reduced liver function
WO2025008465A2 (en) 2023-07-06 2025-01-09 Numares Ag Use of a biomarker for determining the child-pugh class into which an individual is to be classified
WO2025008464A2 (en) 2023-07-06 2025-01-09 Numares Ag Use of a marker or a marker set for determining the risk of an individual to have ascites
EP4653872A1 (en) * 2024-05-22 2025-11-26 Cristóbal Manuel Richart Jurado A set of biomarkers and an in vitro method for the diagnosis of metabolic dysfunction-associated steatohepatitis (mash)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100279956A1 (en) * 2007-11-02 2010-11-04 Mc Creedy Jr Bruce J Biomarkers For Fatty Liver Disease And Methods Using The Same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2001078652A2 (en) 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2005052575A1 (en) * 2003-11-28 2005-06-09 Pfizer Limited Molecular markers of oxidative stress
US7856319B2 (en) * 2005-02-03 2010-12-21 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of alcoholic steato-hepatitis using biochemical markers
JP5496650B2 (ja) 2006-03-21 2014-05-21 メタボロン インコーポレイテッド サンプル内の個々の要素を識別及び定量化するために分光測定データを分析するシステム、方法及びコンピュータプログラム製品
WO2007136674A1 (en) * 2006-05-19 2007-11-29 The Cleveland Clinic Foundation Detection and monitoring of liver damage
US8658351B2 (en) * 2009-02-06 2014-02-25 Metabolon, Inc. Determining liver toxicity of an agent using metabolite biomarkers
EP2309276A1 (en) * 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
CA2778226A1 (en) * 2009-10-09 2011-04-14 Carolyn Slupsky Methods for diagnosis, treatment and monitoring of patient health using metabolomics
EP3273247A1 (en) * 2010-06-10 2018-01-24 Metanomics Health GmbH Methods for the diagnosis of liver diseases
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
US20150065366A1 (en) * 2011-11-11 2015-03-05 Metabolon, Inc. Biomarkers for Bladder Cancer and Methods Using the Same
US10634686B2 (en) * 2013-09-23 2020-04-28 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers related to organ function
AU2015243857A1 (en) * 2014-04-08 2016-10-20 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100279956A1 (en) * 2007-11-02 2010-11-04 Mc Creedy Jr Bruce J Biomarkers For Fatty Liver Disease And Methods Using The Same

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI721462B (zh) * 2018-09-26 2021-03-11 日商島津製作所股份有限公司 非酒精性脂肪肝疾病的檢測方法、非酒精性脂肪肝疾病檢測用試劑盒和非酒精性脂肪肝疾病檢測用生物標記
CN113195732A (zh) * 2018-12-19 2021-07-30 阿斯利康(瑞典)有限公司 Pnpla3表达的生物标记
CN112712896A (zh) * 2021-03-26 2021-04-27 深圳市绘云生物科技有限公司 用于检测非酒精性脂肪性肝病状态的诊断装置
CN112712896B (zh) * 2021-03-26 2023-03-07 深圳市绘云生物科技有限公司 用于受试体检测非酒精性脂肪性肝病状态的诊断装置及计算机系统
CN113160983A (zh) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 一种代谢相关脂肪性肝病临床预测模型
WO2023097510A1 (zh) * 2021-11-30 2023-06-08 江苏品生医疗科技集团有限公司 预测受试者患有糖尿病的可能性的标记物及其应用

Also Published As

Publication number Publication date
US20170370954A1 (en) 2017-12-28
JP2018502286A (ja) 2018-01-25
EP3221463A4 (en) 2018-07-25
WO2016081534A1 (en) 2016-05-26
EP3221463A1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
CN107002113A (zh) 脂肪肝病的生物标志物和其使用方法
US9977034B2 (en) Biomarkers for fatty liver disease and methods using the same
Zhou et al. Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites
JP2023175853A (ja) 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法
Reis et al. Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease
US8758992B2 (en) Method for the differential diagnosis of non-alcoholic fatty liver disease based on a metabolomic profile
CN105209909A (zh) 与肾功能相关的生物标记及其使用方法
Xu et al. Metabolomic profile for the early detection of coronary artery disease by using UPLC-QTOF/MS
US10534001B2 (en) Methods for detecting ovarian cancer
WO2018007422A1 (en) Identification of human non-alcoholic fatty liver disease (nafld) subtypes
EP2904397B1 (en) Means and methods for diagnosing recurrence of prostate cancer after prostatectomy
US8563318B2 (en) Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
HK40049279A (en) Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
HK1216189B (en) Biomarkers for fatty liver disease and methods using the same
US20210405054A1 (en) Methods for detecting ovarian cancer
AU2012310100A1 (en) Means and methods for assessing kidney toxicity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170801

WD01 Invention patent application deemed withdrawn after publication